HSC01
clear graphic
clear graphic

Estrogen enhancers tied to aggressive breast cancer

Posted: Wednesday, September 18, 2013 · Volume: XLVI · Issue: 19

Share |


CTRC Deputy Director Tim Hui-Ming Huang, Ph.D., said that higher numbers of distant estrogen response elements (DEREs) seem to contribute to tumor development, especially in estrogen receptor-positive breast cancers.
clear graphic
CTRC Deputy Director Tim Hui-Ming Huang, Ph.D., said that higher numbers of distant estrogen response elements (DEREs) seem to contribute to tumor development, especially in estrogen receptor-positive breast cancers. clear graphic

Email Printer Friendly Format
 

Contact: Will Sansom, 210-567-2579

SAN ANTONIO (Aug. 12, 2013) Adding to the picture of what prompts breast cancers to form, researchers from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center San Antonio announced Aug. 12 that "distant estrogen response elements" (DEREs) can act independently of oncogenes to spur tumor development.

DEREs appear to be depots or hubs that remotely and simultaneously control multiple target genes in response to estrogen stimulation, said Pei-Yin Hsu, Ph.D., lead author of the paper in Cancer Cell. As such, they are prime targets for the study of novel therapies for breast cancer and could also be useful in diagnosis.
Related link:

Where DEREs are multiplied or present in abnormal numbers, this contributes to tumor development, especially in estrogen receptor-positive breast cancers, said study senior author Tim Hui-Ming Huang, Ph.D., deputy director of the CTRC.

Decreasing the number of DERE copies could have therapeutic potential to treat women with this aggressive form of cancer, Dr. Huang said.

Research focused on two chromosomes
The researchers analyzed two DERE clusters on human chromosomes 17 and 20. They found that the DEREs induce pro-growth factors and inhibit growth-suppressing genes. "It is worthwhile to note that DERE-DERE interactions, instead of DERE interactions with genes, may also contribute to tumor development," Dr. Hsu said.

The team found a correlation between a subset of DERE-regulated genes and tamoxifen resistance. Tamoxifen is a widely prescribed hormone therapy for breast cancer. It may be possible to evaluate how a woman will respond to tamoxifen by measuring DERE activity, Dr. Hsu said.

Potential biomarkers
In addition, the two DEREs that were studied could turn out to be good biomarkers for whether a woman will develop estrogen receptor-positive breast cancer. "Perhaps we could prevent some cases of this cancer," Dr. Huang said.

Several units of the UT Health Science Center joined in the work, including the Greehey Children's Cancer Research Institute, the Institute of Biotechnology and the Department of Molecular Medicine and Department of Epidemiology and Biostatistics in the School of Medicine.

# # #

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI)-designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net.

 
bottom bar

»printer friendly format...
»view more articles by issue#...
»search articles by keywords...
Arrow - to top
HSC Alert - Sign up today
Calendar of Events
Tell Us Your Story Idea
Submission Guidelines
Arrow - to top